H Lundbeck AS (PK) (HLUYY) Quote

Today at the 52 week high.
Technically very strong as it's under constant accumulation.
It imo, will explode as news of the clinical success of it's Alzheimer drug gets more media exposure.

I would welcome some new posters.
I think you'll love the potential of this stock.
It's a quality gem, imo.

The pattern has been one of under constant accumulation.
Anyday now, perhaps today, we will break the 52w high and that's very bullish, among other technical factors.

Don't be 'scared' or put off buy the share price (the company also pays a dividend), as it will look awfully cheap when they come out of phase III Alzheimer clinicals with continuing dramatic success and eventual FDA approval. The revenue market for such a drug is staggering and my research says we've got a potential monster.
What I'm reading couldn't be more bullish and this is clearly a very high quality, world-wide drug research/development/marketing company, that one's portfolio should definitely be exposed to.

On the other end of the continuum, in terms of the staggering potential unmet medical need market out there, is a stem cell penny stock, ACTC, having consistently incredible success in the lab and now with humans, as the are about to enter accelerated phase II clinicals for Macular Degeneration and Stargadt's disease, affecting billions worldwide.

ACTC is to HLUYY what it was years ago as a developing r and d biotech.
An investor , imo needs to understand this developmental phenomenon in the growth and success of biotechs and have both in their portfolio.

I forgot to add in my post yesterday, that in one of heir research partnerships, they are having excellent clinical success in the experimental Alzheimer drug well into phase II. This would be a blockbuster if their clinical success continues.

IMO, it's fun and potentially lucrative to 'play' promising biotech pennys, but here we have a 50+ year old drug company, in partnerships with others all over the world, that have already developed some great drugs and are on the cusp of truly great things with their heart attack and alzheimer research.

All portfolios, imo, should have an exposure to this kind of quality and potential. And by the way, tghey pay a dividend of .35 , as I recall.

Lunbeck, a Danish company, has been successfully engaged in drug research for many years, not only in it'sown country, but with a total of over 5000 individuals in partnerships with biotechs/pharmas all over the world.
Most recently they were a prime player in the development and marketing of the blockbuster drug, Lexapro, among others.

What especially interests me and it's commercial value is staggering if the drug comes to market, is a drug in phase III testing that extends the 3- hour window for a heart attack patient to get to the hospital for treatment to avoid catastrophic damage, to a 9 hour window. Yes NINE hours.
This, if the tests continue as they have to date, will revolutionize the treatment of cardiac event victims.

HLUYY can be bought like any stock, no special commissions, etc., and, imo, one's portfolio of truly established and continually promising drug companies, should include HLUYY.

I would encourage folks to read SEEKING ALPHA mid february issue
on Lundbeck, HLUYY. Unfortunately the bullish article is available for those with Pro subscriptions to Seeking Alpha.
This is one quality drug company.

Time to look at this quality 'unknown' company'
When the Alzheimer news hits, one will be lucky to get this for 5 times it's price today.
You're lucky enough to be reading this.
Don't be left out.
Do some due diligence.

I am so pleased to be starting this board and introducing this relatively unknown, extremely high quality drug and research company to this board.

HLUYY is currently in phase II for an Alzheimer drug that has had great success in earlier clinical phases.
Results are to be released by the end of 2013.

The commercialization of an Alzheimer drug and the resultant revenue/profit is beyond staggering.
I believe a core position in this proven company is a must for one's portfolio.